Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
– Companies plan to discuss results with regulatory authorities – BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen…